NLY01

Neuraly

Drug Candidate

NLY01_PD

Summary

First-in-Class GLP-1R agonist for Neurodegenerative Disease

Mechanism of Action

Long-acting, microglia-targeted GLP-1R agonist

Indication

Parkinson’s Disease (NLY01-PD)
Alzheimer’s Disease (NLY01-AD)

Development Stage

Phase II
Phase II

Background

Alternative strategies are needed → Targeting Neurotoxic Microglia-Astrocytes in PD and AD

Description

  • · Activated M1 microglia and A1 astrocytes play critical roles in PD and AD
  • · NLY01 binds upregulated GLP-1R in activated microglia (by α-Syn fibrils in PD and β-amyloid fibrils in AD patients) and effectively shuts down microglial activation
  • · In turn, NLY01 prevents A1 astrocyte formation and subsequent neuronal death -> Halt or Slow Down the progression of PD/AD

Related Articles

  • · Nature Medicine, volume 24, pages 931–938 (2018)
  • · Nature Medicine, volume 24, pages 900–902 (2018)